Boryung Corp secured its first global contract manufacturing agreement for oral medications, partnering with Germany’s Cheplapharm to produce Zyprexa tablets for distribution across 46 countries starting in the fourth quarter of 2025.
The South Korean pharmaceutical company will manufacture the schizophrenia treatment at its Yesan campus under the deal announced Thursday. The agreement marks Boryung’s expansion beyond injectable drug manufacturing into oral formulations for the global contract development and manufacturing organization market.
Cheplapharm acquired worldwide rights to Zyprexa from Eli Lilly in 2023 for $1.35 billion, excluding Korea. The German company recorded sales of approximately 2.4 trillion won ($1.8 billion) last year and distributes medicines to more than 145 countries.
Boryung already holds Korean rights to Zyprexa, which it acquired from Lilly in 2021. The company completed technology transfer and quality evaluation processes before beginning domestic production at Yesan this year.
The Yesan facility has earned European Union Good Manufacturing Practice certification for its cancer drug injection lines and is pursuing similar approvals for oral drug production. Boryung is also seeking certification from Brazil’s health surveillance agency to access Latin American markets.
This follows Boryung’s contract manufacturing agreement with Taiwan’s Lotus Pharmaceutical for injectable cancer drugs, with supply beginning in 2026. The company has been executing what it calls a Legacy Brands Acquisition strategy, securing rights to established drugs from multinational pharmaceutical companies and transferring production to Korea.
